Back to Search Start Over

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome.

Authors :
Fanale D
Fiorino A
Incorvaia L
Dimino A
Filorizzo C
Bono M
Cancelliere D
Calò V
Brando C
Corsini LR
Sciacchitano R
Magrin L
Pivetti A
Pedone E
Madonia G
Cucinella A
Badalamenti G
Russo A
Bazan V
Source :
Frontiers in oncology [Front Oncol] 2021 Jun 11; Vol. 11, pp. 682445. Date of Electronic Publication: 2021 Jun 11 (Print Publication: 2021).
Publication Year :
2021

Abstract

About 10-20% of breast/ovarian (BC/OC) cancer patients undergoing germline BRCA1/2 genetic testing have been shown to harbor Variants of Uncertain Significance (VUSs). Since little is known about the prevalence of germline BRCA1/2 VUS in Southern Italy, our study aimed at describing the spectrum of these variants detected in BC/OC patients in order to improve the identification of potentially high-risk BRCA variants helpful in patient clinical management. Eight hundred and seventy-four BC or OC patients, enrolled from October 2016 to December 2020 at the "Sicilian Regional Center for the Prevention, Diagnosis and Treatment of Rare and Heredo-Familial Tumors" of University Hospital Policlinico "P. Giaccone" of Palermo, were genetically tested for germline BRCA1/2 variants through Next-Generation Sequencing analysis. The mutational screening showed that 639 (73.1%) out of 874 patients were BRCA - w.t. , whereas 67 (7.7%) were carriers of germline BRCA1/2 VUSs, and 168 (19.2%) harbored germline BRCA1/2 pathogenic/likely pathogenic variants. Our analysis revealed the presence of 59 different VUSs detected in 67 patients, 46 of which were affected by BC and 21 by OC. Twenty-one (35.6%) out of 59 variants were located on BRCA1 gene, whereas 38 (64.4%) on BRCA2 . We detected six alterations in BRCA1 and two in BRCA2 with unclear interpretation of clinical significance. Familial anamnesis of a patient harboring the BRCA1 -c.3367G>T suggests for this variant a potential of pathogenicity, therefore it should be carefully investigated. Understanding clinical significance of germline BRCA1/2 VUS could improve, in future, the identification of potentially high-risk variants useful for clinical management of BC or OC patients and family members.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Fanale, Fiorino, Incorvaia, Dimino, Filorizzo, Bono, Cancelliere, Calò, Brando, Corsini, Sciacchitano, Magrin, Pivetti, Pedone, Madonia, Cucinella, Badalamenti, Russo and Bazan.)

Details

Language :
English
ISSN :
2234-943X
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
34178674
Full Text :
https://doi.org/10.3389/fonc.2021.682445